GEN Exclusives

More »

GEN News Highlights

More »
Jun 23, 2010

Lonza Negotiates License to Axxam’s Photoproteins for Clonetics Primary Sensor Cells

  • Axxam and Lonza signed a license agreement that will allow the latter to include Axxam’s Photina®, iPhotina®, and Clytin® photoproteins as calcium biosensors in its range of Clonetics® primary cells.

    The Photina technology is a Ca2+-activated photoprotein optimized for the generation of precise Ca2+ mobilization assays for high-throughput screening, Axxam claims. The product  combines part of the obelin photoprotein with a part of clytin. iPhotina has been developed as an improved version of Photina that retains the same mechanism of action and characteristics but with an increased light release.

    Lonza’s Clonetics Primary Sensors have been developed to help researchers measure drug targets in a biologically relevant environment, the firm states. The sensor is added to the cell by Lonza using the Amaxa Nucleofector® technology. The substrate is then added before the cells are frozen, ready for use.

    “Our newly introduced Clonetics Primary Sensors range of products allows customers to access their primary cells of choice and measure endogenous receptor activity using the same technologies and protocols that they are used to using with overexpressing cell lines,” remarks Leon de Bruin, senior product manager for Lonza’s drug discovery marketing group.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?